Conference Spotlight

Key takeaways, industry discussions, and insights from major regulatory conferences.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Conference Spotlight

ICH Q9: Quality Risk Management Revision Focuses on Six Topic Areas

No items found.
Conference Spotlight

What is the Best Way to Prepare for an FDA inspection?

No items found.
Conference Spotlight

UDI Compliance for Medical Devices: Part I

No items found.
Conference Spotlight

FDA on Cross-Contamination, Sustainable Compliance, and Contract Ops

No items found.
Conference Spotlight

Quality Culture Assessments and Records Request Responses

No items found.
Conference Spotlight

FDA Regulators Address Data Integrity and Lab Audit Trails

No items found.
Conference Spotlight

Postmarket Medical Device Surveillance at CDRH: Part II

No items found.
Conference Spotlight

Postmarket Medical Device Surveillance at CDRH: Part I

No items found.
Conference Spotlight

Best Practices for Responding to a Medical Device FDA 483

No items found.
Conference Spotlight

EU MDR and Economic Operators for Medical Devices

No items found.
Conference Spotlight

Process Capability in Focus in FDA Device Inspections

No items found.
Conference Spotlight

Many Device Cleaning Validation Programs Need Work, FDA Investigator Says

No items found.
Conference Spotlight

Navigating a Regulatory Path to Market Through EU MDR Article 117

No items found.
Conference Spotlight

ORA Targets CAPA Effectiveness Check Deficiencies

No items found.
Conference Spotlight

Pharma Must Develop Quality Leaders: Here is One Approach

No items found.
Conference Spotlight

UK’s MHRA Reinventing Itself as Sovereign Regulator

No items found.
Conference Spotlight

How to Assess and Advance a Pharma Company’s Quality Maturity

No items found.
Conference Spotlight

Do FDA Policies Discourage Pharma from Deploying New Technologies?

No items found.